Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals' Board has approved the acquisition of 40,95,180 equity shares (20.42%) in its subsidiary Zuventus Healthcare Limited from individual shareholders, taking its holding from 79.58% to 100%. The deal is valued at an aggregate cash consideration of Rs. 724.9 crores, payable in one or more tranches. Zuventus reported a turnover of Rs. 1,079.9 crores and a profit after tax of Rs. 134.8 crores for FY25. The transaction is classified as a related party deal as Zuventus is already a subsidiary, and will be executed at arm's length pricing. The acquisition is expected to be completed on or before September 30, 2025.
This is a consolidation move that simplifies group structure by making a profitable subsidiary (Zuventus) wholly-owned, allowing Emcure to capture 100% of its earnings going forward. However, it involves a cash outflow of nearly Rs. 725 crores, which could modestly pressure short-term liquidity. The deal is at arm's length and is unlikely to materially impact the stock price given Zuventus is already consolidated in Emcure's financials.